Evidence map›Paper›PMID 40335667›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2025

Antipsychotics cause reversible structural brain changes within one week.

Pierluigi Selvaggi, Martin Osugo, Uzma Zahid, Ottavia Dipasquale, Thomas Whitehurst, Ellis Onwordi, George Chapman, Valeria Finelli, Ben Statton, Tobias C Wood and 5 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pierluigi SelvaggiDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. pierluigi.selvaggi@kcl.ac.uk.ORCID http://orcid.org/0000-0001-9069-0700
Martin OsugoMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0002-5462-8464
Uzma ZahidMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
Ottavia DipasqualeDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Thomas WhitehurstMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0002-7005-902X
Ellis OnwordiMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
George ChapmanMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
Valeria FinelliMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
Ben StattonMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0001-5118-7977
Tobias C WoodDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Matthew B WallInvicro, London, UK.
Robin MurrayMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0003-0829-0519
Mitul A MehtaDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.ORCID http://orcid.org/0000-0003-1152-5323
Tiago Reis MarquesMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0003-0602-7661
Oliver D HowesMRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom. oliver.howes@kcl.ac.uk.ORCID http://orcid.org/0000-0002-2928-1972

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 964874Maudsley Charity 666RCUK | Medical Research Council (MRC) MC_U120097115Wellcome TrustWellcome Trust (Wellcome) 094849/Z/10/Z
6 · The paper itself

Abstract

Determining the effects of antipsychotics on MRI brain structural metrics without the potential confounding effects related to the natural course of a psychotic illness is challenging. However, it is crucial to understand these effects to interpret the results of cross-sectional and longitudinal studies in medicated patients and, ultimately, to understand better the biological mechanisms driving antipsychotics' effects. In this work, we aim to determine whether exposure to antipsychotics is associated with alterations in brain MRI structural metrics in the absence of disease effects. A randomized, double-blind, counter-balanced order, crossover, placebo-controlled study in healthy volunteers was performed. The study comprised two arms. Within arms, participants were randomized to receive daily doses of either the active compound (Arm 1= amisulpride 400 mg/day, N = 24; Arm 2= aripiprazole 10 mg/day, N = 24) for one week, followed by placebo or vice versa. We found increased MRI volume estimates in the left putamen and in the right caudate in the amisulpride condition as compared to placebo and increased right putamen volume estimates after aripiprazole compared to placebo. No other effects were found in cortical volume estimates, cortical thickness, cortical surface area, and T1-relaxation time. Striatal changes reversed within weeks of drug withdrawal. Short-term exposure to either one of two different antipsychotics results in a transient increase in striatal volume measured with T1-weighted MRI that normalizes rapidly on stopping treatment without cortical changes. Our findings suggest that striatal volumetric MRI differences detected in people with schizophrenia taking antipsychotics are, at least in part, attributable to pharmacological effects.

Indexed as

Antipsychotic AgentsAripiprazoleBrainSulpirideAdultAmisulprideCross-Over StudiesDouble-Blind MethodFemaleHumansMagnetic Resonance ImagingMaleYoung AdultAmisulprideAntipsychotic AgentsAripiprazoleSulpiride

Identifiers

PMID40335667
PMCPMC12170900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.